Literature DB >> 9001903

Immunotherapy of leprosy.

K Katoch1.   

Abstract

Immunotherapy aims to modify the defective cell-mediated immune response in a section of leprosy cases. This presentation reviews the various immunomodulators developed/ investigated for this purpose. Among the various mycobacterial agents, BCG, BCG + M.leprae, Mycobacterium w, ICRC bacillus and M.vaccae have been tried in leprosy patients and varying degree of beneficial effects on bacterial killing and clearance have been observed. Studies carried out at CJIL, Agra and elsewhere suggest an important role for these mycobacteria as immunotherapeutic agents. Other mycobacteria-M.habana, M.phlei, M.gordonae-have also been reported to be promising experimentally. In addition, various drugs such as levamisole, zinc and RACA 854 have been observed to have immunomodulatory role in leprosy cases. Other promising immunomudlators include transfer factor, interferon gamma, interleukin 2 and acetoacetylated M.leprae. The progress achieved shows that immunotherapy may be considered as adjunct to chemotherapy to enhance bacterial killing as well as bacterial clearance and thus may be recommended to shorten the treatment period, specially in bacilliferous leprosy cases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9001903

Source DB:  PubMed          Journal:  Indian J Lepr        ISSN: 0254-9395


  5 in total

1.  Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance.

Authors:  C Szeto; K M Gillespie; P W Mathieson
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

Review 2.  Minimal change nephropathy and focal segmental glomerulosclerosis.

Authors:  Peter W Mathieson
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

3.  Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells.

Authors:  L-Y Chen; Y-L Lin; B-L Chiang
Journal:  Clin Exp Immunol       Date:  2007-11-14       Impact factor: 4.330

4.  Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants.

Authors:  Mohammad Hossein Somi; Babak Hajipour
Journal:  ISRN Gastroenterol       Date:  2012-09-18

5.  Levamisole usage as an adjuvant to hepatitis B vaccine in hemodialysis patients, yes or no?

Authors:  Houshang Sanadgol
Journal:  Nephrourol Mon       Date:  2012-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.